Back to Authors

Seiwert, Tanguy Y.

0000-0001-7919-8272

A5008467612 | I40347166

Mayo Clinic

University of Chicago

Citations 3

A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6060-6060

10.1200/jco.2015.33.15_suppl.6060

Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6089-6089

10.1200/jco.2014.32.15_suppl.6089

A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6031-6031

10.1200/jco.2018.36.15_suppl.6031